Navigation Links
Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials

is designed, studied and manufactured by Abbott Vascular. Abbott supplies a private-labeled version of XIENCE V to Boston Scientific, called the PROMUS(TM) Everolimus-Eluting Coronary Stent System, as part of a distribution agreement established between the two companies last year.

About the SPIRIT Family of Trials

SPIRIT FIRST is a randomized trial comparing the XIENCE V Everolimus Eluting Coronary Stent System with the MULTI-LINK VISION metallic stent system. SPIRIT II was a randomized clinical trial evaluating XIENCE V versus TAXUS in Europe and Asia Pacific. Professor Patrick Serruys of Rotterdam is the principal investigator in SPIRIT FIRST and SPIRIT II.

SPIRIT III is a large-scale randomized pivotal clinical trial comparing XIENCE V to TAXUS in the United States and Japan. SPIRIT IV is a randomized trial currently enrolling patients and will evaluate the safety and efficacy of XIENCE V for the treatment of coronary artery disease in a more complex patient population in the United States. Professor Gregg Stone of Medical Center, N.Y., is the principal investigator in SPIRIT III and SPIRIT IV.

SPIRIT V is an international clinical trial currently enrolling patients that will provide additional data on clinical experience with XIENCE V at 100 clinical sites throughout Europe, Asia, Canada and Latin America.

SPIRIT WOMEN is the world's first drug-eluting stent trial to study only women and will evaluate the characteristics of women undergoing stent implantation as well as the performance of XIENCE V in those patients in Europe, Asia-Pacific, Canada and Latin America.

For images of Abbott's investigational XIENCE V stent system and other information, please visit the company's online newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care bu
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/11/2014)... LONDON , July 11, 2014 ... ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average ... 500 closed at 1,964.68, down 0.41%. The losses were broad ... in negative. The S&P 500 Health Care Sector Index ended ... advanced 2.75% in the last one month. Investor-Edge has initiated ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... indicate early non-responders unlikely to subsequently,respond, have ... earlier change in treatment strategy, COLORADO SPRINGS, ... presented at the 2007 International Congress on,Schizophrenia ... assessed earlier than is presently thought, and,challenge ...
... Time Reduced By an Average of More ... PARK, N.C., April 02, 2007 /PRNewswire/ --,Adding ... XL 24-Hour(TM) Extended-Release Tablets to,Parkinson's patients' existing ... patients to continue,their daily activities for a ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5
(Date:7/11/2014)... screened positive for a history of hazardous or binge ... percent after receiving mobile phone text messages following a ... published online yesterday in Annals of Emergency Medicine ... Adult Emergency Department Patients: A Randomized Clinical Trial "). ... adults ages 18 to 24 visit ERs and up ...
(Date:7/11/2014)... 11, 2014 With the arrival of ... seeking cosmetic surgery and hair transplant procedures, up 80 ... expansive range of medical tourism destinations, the company is ... costs and achieve the look they have always ... the top name in the medical tourism industry, VisitandCare.com ...
(Date:7/11/2014)... By Steven Reinberg ... -- Stress, hostility and depression may increase the risk for ... depression seemed to raise the risk of a stroke or ... also found that stress apparently raised stroke or TIA risk ... said. A TIA is a mini-stroke caused by a temporary ...
(Date:7/11/2014)... July 11, 2014 Fadhits.com, the distinguished ... elegant assortment of lace holiday dresses . To ... are now offered at discounted prices, up to 65% ... can enjoy this special offer. , Fadhits.com is ... special occasion dresses for the global clients. All its ...
(Date:7/11/2014)... UC San Francisco shows that an "expressive therapy" ... women living with HIV disclose their health status ... safety and quality of their relationships., "Medication alone ... Edward L. Machtinger, MD, director of the Women,s ... our patients are on effective antiretroviral therapy but ...
Breaking Medicine News(10 mins):Health News:Text message medicine: Texts from the ER can reduce binge drinking 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:'Expressive therapy" intervention assists women living with HIV 2
... ... their products stocked in more than 10,000 retail outlets nationwide working closely with major ... ... brand Intellicig has signed an exclusive deal which will see their products stocked in ...
... , , , BEIJING , ... SVA),("Sinovac" or the "Company"), a leading China -based vaccine ... was,closed on February 2, 2010 . Sinovac received net ... and commissions and,estimated offering expenses payable by the Company, which ...
... , NASHVILLE, Tenn. , Feb. 2 ... its common stock cash dividend for the quarter ended December ... per share, is payable on March 4, 2010 ... , Healthcare Realty Trust is a real estate investment trust that ...
... PHILADELPHIA - For the first time, researchers from the ... three different degenerative brain disorders are linked by a ... Elk-1, was found in clumps of misshaped proteins that ... Huntington,s disease. "These results suggest a molecular ...
... ... accreditation to the Oakland University William Beaumont School of Medicine. , ... (Vocus) February 2, 2010 -- The Liaison ... Beaumont School of Medicine ., , , , ,The LCME is the national accrediting authority ...
... one scan is usually enough, but editorial begs to differ ... a paper in a medical journal to be accompanied by ... might be "overly simple and consequently not clinically useful." , ... 3 issue of the Journal of the American Medical ...
Cached Medicine News:Health News:Intellicig Clinches Exclusive Deal with Retail Distribution-Giant to Distribute Their Industry Leading Electronic Cigarettes 2Health News:Intellicig Clinches Exclusive Deal with Retail Distribution-Giant to Distribute Their Industry Leading Electronic Cigarettes 3Health News:Sinovac Announces Closing of Common Share Offering 2Health News:Sinovac Announces Closing of Common Share Offering 3Health News:Healthcare Realty Trust Announces Fourth Quarter Dividend 2Health News:3 brain diseases linked by toxic form of same neural protein 2Health News:Oakland University William Beaumont School of Medicine Reaches Development Milestone 2Health News:Analysis Examines Ultrasound Use for Blood Clots 2Health News:Analysis Examines Ultrasound Use for Blood Clots 3
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Perfect for use in the E.R. Stabilizes collateral ligament strains in seconds and allows hand and finger function. Made from 1/8" AliPlast™ PXE. Can be scissor trimmed....
... Slip on, warm with a ... to fit. Splint hardens as ... and reposition. Unique fiberglass knit ... polymer Straps included. Tape, 1" ...
... The Blue Line ThumStay offers thumb and ... with soft, breathable foam. Lightweight stays provide ... and can easily be contoured for proper ... with deQuervain's tenosynovitis, tendinitis, CMC joint arthritis, ...
Medicine Products: